Is Aeglea Bio Therapeutics Inc (AGLE) Stock a Smart Investment Wednesday?
Wednesday, December 08, 2021 11:55 AM | InvestorsObserver Analysts
Mentioned in this article
Aeglea Bio Therapeutics Inc (AGLE) stock is down -55.44% over the last 12 months, and the average rating from Wall Street analysts is a Strong Buy. InvestorsObserver’s proprietary ranking system, gives AGLE stock a score of 27 out of a possible 100.
That rank is chiefly influenced by a short-term technical score of 1. AGLE's rank also includes a long-term technical score of 1. The fundamental score for AGLE is 78. In addition to the average rating from Wall Street analysts, AGLE stock has a mean target price of $13.25. This means analysts expect the stock to gain 272.19% over the next 12 months.
AGLE has an Overall Score of 27. Find out what this means to you and get the rest of the rankings on AGLE!
Aeglea Bio Therapeutics Inc (AGLE) stock is down -2.2% while the S&P 500 is down -0.06% as of 11:54 AM on Wednesday, Dec 8. AGLE is down -$0.08 from the previous closing price of $3.64 on volume of 370,420 shares. Over the past year the S&P 500 has risen 26.52% while AGLE is down -55.44%. AGLE lost -$1.27 per share in the over the last 12 months.
Click Here to get the full Stock Report for Aeglea Bio Therapeutics Inc stock.
Share this article:
Stay In The Know
Subscribe to our daily morning update newsletter and never miss out on the need-to-know market news, movements, and more.
Thank you for signing up! You're all set to receive the Morning Update newsletter
